Randox Laboratories has launched Evidence Evolution, the latest addition to the Evidence family of immunoassay analysers, at AACC Clinical Lab Expo in Anaheim, California.
The company claimed that the Evidence Evolution is the first fully automated, random access biochip testing platform.
Randox will exhibit its complete product range, from clinical chemistry analysers and reagents to quality control and life sciences, at the event.
The Evidence Evolution is said to offer complete consolidation on one platform.
Biochip array technology is said to provide limitless multiplex capabilities enabling simultaneous testing from a single small-volume sample.
Coupling such technology with Randox's test menu enables the Evidence Evolution to provide laboratories with patient profiling capabilities while saving time and costs.
Advanced performance, productivity and quality are key benefits of the Evidence Evolution, according to Randox.
This is achieved through the integration of e-touch software, advanced precision bio-drive robotics and true random access capabilities.
The system also hosts high quality, highly secure remote access diagnostics, ensuring quick access to advanced technical support.